Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference Jun 07, 2021 Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity May 20, 2021 Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) May 18, 2021 Nektar Therapeutics Reports First Quarter 2021 Financial Results May 06, 2021 Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets Apr 27, 2021 Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results Feb 25, 2021 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets Feb 18, 2021 Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) Feb 17, 2021 Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer Feb 17, 2021 Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference Jan 06, 2021 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »